ArticleNeuropsychiatric disease and treatment2006
Prophylaxis of migraine.
Article in Neuropsychiatric disease and treatment, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.Cephalalgia : an international journal of headache · 2022Trial
- Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.Headache · 2021Trial
- Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.The journal of headache and pain · 2018Trial
- The synergistic effects of ω-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-α gene expression and serum level in migraine patients.Immunogenetics · 2017Trial
- Effectiveness of an Oral Supplementation of Phycocyanin and Palmitoylethanolamide for a Short-Term Prophylaxis of Menstrual Migraine: A Retrospective Observational Study.Biomedicines · 2026Article
- Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment.Headache · 2025Article
- Exploring the Impact of Osteopathic Manipulative Treatment on Chronic Migraine Relief: A Case Study.Cureus · 2025Article
- Upholding or Breaking the Law of Superposition in Pharmacokinetics.Biomedicines · 2024Review
- The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education.American journal of pharmaceutical education · 2018Review
- Review
- Preventive agents for migraine: focus on the antiepileptic drugs.Journal of central nervous system disease · 2012Article
- Central sensitization as a component of post-deployment syndrome.NeuroRehabilitation · 2012Review
- Migraine - a suitable case for treatment?Neuropsychiatric disease and treatment · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common primary headache disorder often associated with significant disability. While many individuals are able to limit therapy to acute treatment of attacks, others need medication to reduce the attack frequency and/or severity. Evidence-based guidelines exist regarding indications and goals for migraine preventive treatment. The specific prophylactic approach needs to be individualized taking into account multiple variables. Medications used in this task vary widely in proven efficacy and presumed mechanisms of action. This review's goal is to discuss the issues that guide the decision-making process in migraine preventive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.